107 related articles for article (PubMed ID: 23588493)
1. Identification of tumorigenic and therapeutically actionable mutations in transplantable mouse tumor cells by exome sequencing.
Bhadury J; López MD; Muralidharan SV; Nilsson LM; Nilsson JA
Oncogenesis; 2013 Apr; 2(4):e44. PubMed ID: 23588493
[TBL] [Abstract][Full Text] [Related]
2. Genomic sequencing of key genes in mouse pancreatic cancer cells.
Wang Y; Zhang Y; Yang J; Ni X; Liu S; Li Z; Hodges SE; Fisher WE; Brunicardi FC; Gibbs RA; Gingras MC; Li M
Curr Mol Med; 2012 Mar; 12(3):331-41. PubMed ID: 22208613
[TBL] [Abstract][Full Text] [Related]
3. Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer.
Bousquet MS; Ma JJ; Ratnayake R; Havre PA; Yao J; Dang NH; Paul VJ; Carney TJ; Dang LH; Luesch H
ACS Chem Biol; 2016 May; 11(5):1322-31. PubMed ID: 26938486
[TBL] [Abstract][Full Text] [Related]
4. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
Pécuchet N; Legras A; Laurent-Puig P; Blons H
Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
[TBL] [Abstract][Full Text] [Related]
5. A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.
Šuštić T; van Wageningen S; Bosdriesz E; Reid RJD; Dittmar J; Lieftink C; Beijersbergen RL; Wessels LFA; Rothstein R; Bernards R
Genome Med; 2018 Nov; 10(1):90. PubMed ID: 30482246
[TBL] [Abstract][Full Text] [Related]
6. RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
Fang B
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):27-38. PubMed ID: 26350096
[TBL] [Abstract][Full Text] [Related]
7. Massively parallel sequencing of the mouse exome to accurately identify rare, induced mutations: an immediate source for thousands of new mouse models.
Andrews TD; Whittle B; Field MA; Balakishnan B; Zhang Y; Shao Y; Cho V; Kirk M; Singh M; Xia Y; Hager J; Winslade S; Sjollema G; Beutler B; Enders A; Goodnow CC
Open Biol; 2012 May; 2(5):120061. PubMed ID: 22724066
[TBL] [Abstract][Full Text] [Related]
8. Exome-wide Sequencing Shows Low Mutation Rates and Identifies Novel Mutated Genes in Seminomas.
Cutcutache I; Suzuki Y; Tan IB; Ramgopal S; Zhang S; Ramnarayanan K; Gan A; Lee HH; Tay ST; Ooi A; Ong CK; Bolthouse JT; Lane BR; Anema JG; Kahnoski RJ; Tan P; Teh BT; Rozen SG
Eur Urol; 2015 Jul; 68(1):77-83. PubMed ID: 25597018
[TBL] [Abstract][Full Text] [Related]
9. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.
Hunter SM; Anglesio MS; Ryland GL; Sharma R; Chiew YE; Rowley SM; Doyle MA; Li J; Gilks CB; Moss P; Allan PE; Stephens AN; Huntsman DG; deFazio A; Bowtell DD; ; Gorringe KL; Campbell IG
Oncotarget; 2015 Nov; 6(35):37663-77. PubMed ID: 26506417
[TBL] [Abstract][Full Text] [Related]
10. Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation.
Martin ES; Belmont PJ; Sinnamon MJ; Richard LG; Yuan J; Coffee EM; Roper J; Lee L; Heidari P; Lunt SY; Goel G; Ji X; Xie Z; Xie T; Lamb J; Weinrich SL; VanArsdale T; Bronson RT; Xavier RJ; Vander Heiden MG; Kan JL; Mahmood U; Hung KE
Clin Cancer Res; 2013 Jun; 19(11):2929-40. PubMed ID: 23403635
[TBL] [Abstract][Full Text] [Related]
11. IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.
Li Y; Buijs-Gladdines JG; Canté-Barrett K; Stubbs AP; Vroegindeweij EM; Smits WK; van Marion R; Dinjens WN; Horstmann M; Kuiper RP; Buijsman RC; Zaman GJ; van der Spek PJ; Pieters R; Meijerink JP
PLoS Med; 2016 Dec; 13(12):e1002200. PubMed ID: 27997540
[TBL] [Abstract][Full Text] [Related]
12. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
[TBL] [Abstract][Full Text] [Related]
13. MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling.
McNew KL; Whipple WJ; Mehta AK; Grant TJ; Ray L; Kenny C; Singh A
Mol Cancer Res; 2016 Dec; 14(12):1204-1216. PubMed ID: 27655129
[TBL] [Abstract][Full Text] [Related]
14. Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
Bessette DC; Tilch E; Seidens T; Quinn MC; Wiegmans AP; Shi W; Cocciardi S; McCart-Reed A; Saunus JM; Simpson PT; Grimmond SM; Lakhani SR; Khanna KK; Waddell N; Al-Ejeh F; Chenevix-Trench G
PLoS One; 2015; 10(5):e0125232. PubMed ID: 25969993
[TBL] [Abstract][Full Text] [Related]
15. Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.
Shrestha R; Llaurado Fernandez M; Dawson A; Hoenisch J; Volik S; Lin YY; Anderson S; Kim H; Haegert AM; Colborne S; Wong NKY; McConeghy B; Bell RH; Brahmbhatt S; Lee CH; DiMattia GE; Le Bihan S; Morin GB; Collins CC; Carey MS
Cancer Res; 2021 Apr; 81(7):1681-1694. PubMed ID: 33441310
[TBL] [Abstract][Full Text] [Related]
16. Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.
Suzawa K; Offin M; Lu D; Kurzatkowski C; Vojnic M; Smith RS; Sabari JK; Tai H; Mattar M; Khodos I; de Stanchina E; Rudin CM; Kris MG; Arcila ME; Lockwood WW; Drilon A; Ladanyi M; Somwar R
Clin Cancer Res; 2019 Feb; 25(4):1248-1260. PubMed ID: 30352902
[TBL] [Abstract][Full Text] [Related]
17. IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples.
Hintzsche J; Kim J; Yadav V; Amato C; Robinson SE; Seelenfreund E; Shellman Y; Wisell J; Applegate A; McCarter M; Box N; Tentler J; De S; Robinson WA; Tan AC
J Am Med Inform Assoc; 2016 Jul; 23(4):721-30. PubMed ID: 27026619
[TBL] [Abstract][Full Text] [Related]
18. Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.
Dong LQ; Shi Y; Ma LJ; Yang LX; Wang XY; Zhang S; Wang ZC; Duan M; Zhang Z; Liu LZ; Zheng BH; Ding ZB; Ke AW; Gao DM; Yuan K; Zhou J; Fan J; Xi R; Gao Q
J Hepatol; 2018 Jul; 69(1):89-98. PubMed ID: 29551704
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
20. Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomes.
Cheng F; Zhao J; Zhao Z
Brief Bioinform; 2016 Jul; 17(4):642-56. PubMed ID: 26307061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
